India

The notification by the Central Government stated “the said Expert Committee considered this FDC as irrational”

The countries on the list include the US, UK, Japan, Australia, Canada and the EU

Dr Deevanshu Shrivastava, Associate Dean, GD Goenka University, elaborates on the crucial role of IPR in India pharma Inc’s…

Dr Prudwidhar S, Country Medical Affairs Director, Miltenyi Biotec emphasises why successful implementation of CAR-T cell therapy…

The Finance Minister announced the Budget for 2024-25 on July 23, during the Monsoon Session of Parliament

Anil Matai, Director General, OPPI shares an optimistic outlook for further enhancements in quality healthcare through continued…

Exports are being made, particularly to the EU, UAE, and Japan, while other markets like Malaysia, Southeast Asia, and Taiwan are…

Hisham Mundol, Chief Advisor, Environmental Defense Fund, India

Dr Ashok Omray, Pharma Consultant, points out that despite significant advancements, the Indian pharma industry grapples with…

By Sidharrth Shankar, Partner, JSA Advocates and Solicitors

Executive heads of companies must sign and submit the declarations by June 30

This course aims to provide a comprehensive overview of the concepts and steps involved in the design, development and…

US-focused pharma companies to sustain their revenue improvement trend in FY25 on account of heightened drug shortages in the US…

Glenmark will manufacture and supply Remogliflozin while Torrent will market the drug under its own trademark 'Zucator' in India…